Your Notifications
All done, no notifications

CAR-T Cost in United Kingdom

Costs starts from USD373000 to USD475000
Filters

How Much Does CAR-T Cost in United Kingdom?

The cost of CAR-T in United Kingdom is USD 373000 - USD 475000

Additionally, factors like the duration of treatment, the need for follow-up care, and the use of advanced technologies or specialized treatments can further influence the overall cost.

Factors Influencing the Cost of CART:

CART is an acronym for a promising experimental type of cancer treatment called Chimeric Antigen Receptor T-cell therapy and mainly targets blood malignancies such as leukemia and lymphoma. This therapy is done by modifying the patient’s T-cells (one form of white blood cells) in the laboratory and making them have a receptor that homes in on cancerous cells. These engineered T-cells are then transduced back into the patient, they go on to hunt for cancer cells to kill.

CART therapy is rather effective, particularly in the cases of the treatment efficacy of which has not been rather impressive. It is individual treatment, which means that is independent of the cancer type in the patient. There are risks for cytokine release syndrome (CRS), as well as neurotoxicity that should be closely watched out for, but this option is hopeful for cancer patients who normally cannot be treated with conventional treatments.

Cost of CAR-T in Major Cities of United Kingdom

CityMinimum Cost (USD)Minimum Cost (GBP)Maximum Cost (USD)Maximum Cost (GBP)
LondonUSD 373000276020USD 475000351500

CAR-T Cost : A Global Comparison

CountryMinimum CostMinimum Local CurrencyMaximum CostMaximum Local Currency
Czechiaget request
IndiaUSD 80000INR 6851200USD 120000INR 10276800
LithuaniaUSD 300000LTL 1026210USD 500000LTL 1710350
MalaysiaUSD 75000MYR 318000USD 125000MYR 530000
Saudi ArabiaUSD 373000SAR 1398750USD 500000SAR 1875000
Singapore - - USD 475000SGD 612750
SpainUSD 30000ESP 4411197USD 56000ESP 8234234
SwitzerlandUSD 373000CHF 309590USD 500000CHF 415000
ThailandUSD 150000THB 4906500USD 470000THB 15373700
TunisiaUSD 100000TND 298000USD 200000TND 596000
TurkeyUSD 25000TRY 976500USD 55000TRY 2148300
United Arab EmiratesUSD 200000AED 734000USD 300000AED 1101000
United KingdomUSD 373000GBP 276020USD 475000GBP 351500

Need Help Planning Your Treatment Abroad?

Your 24/7 AI Health Assistant

CAR T-cell therapy represents a groundbreaking approach to harnessing the power of the body's immune system to combat cancer. By modifying T cells, a subset of white blood cells, in a laboratory setting, these cells are empowered to recognize and eliminate cancer cells with precision. Often categorized as a form of cell-based gene therapy, CAR T-cell therapy involves altering the genetic makeup of T cells, equipping them with the ability to target specific cancer antigens.

This innovative treatment has demonstrated remarkable efficacy, particularly in cases where conventional therapies have proven ineffective. Its ability to reprogram the immune system to target and destroy cancer cells marks a significant advancement in cancer treatment strategies.

Classification:

CAR T cell therapy is classified as follows:

  • Structure-based classification:
  • First-generation CAR T-cells: These CAR T-cells typically consist of an antigen-binding domain (single-chain variable fragment, scFv) linked to a T-cell activation domain, such as the CD3ζ chain. They lack additional co-stimulatory domains.
  • Second-generation CAR T-cells: These CAR T-cells include an additional co-stimulatory domain, such as CD28 or 4-1BB (CD137), along with the CD3ζ chain. The presence of co-stimulatory domains enhances T-cell activation and persistence.
  • Third-generation CAR T-cells: These CAR T-cells incorporate two co-stimulatory domains along with the CD3ζ chain, aiming to further enhance T-cell function and anti-tumor activity.

Antigen-based classification: It includes

  • CD19-targeted CAR T-cells: CD19 is a common target for CAR T-cell therapy and is used in the treatment of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma.
  • Other antigen-targeted CAR T-cells: CAR T-cells can be engineered to target a variety of antigens expressed on cancer cells, including but not limited to BCMA (B-cell maturation antigen), CD22, CD30, and EGFRvIII.

CAR T-cell therapy is primarily used to treat blood cancers, such as multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukaemia. The patient's own T cells are reprogrammed to identify and destroy cancer cells, cause remission, enhance survival, and have a plan B in case other treatments fail.

Patients with blood cancers who relapsed or are refractory must consult an oncologist to determine candidacy for CAR T therapy, especially if they have failed to respond to traditional treatments (i.e., chemotherapy, radiation, or stem cell transplant). Evaluation is warranted for symptoms such as loss of weight, swelling of lymph nodes, recurrent infection, chronic fatigue, or spontaneous bruising.

Screening tests consist of imaging, bone marrow biopsy, and blood work.Leukapheresis is utilised to harvest T cells from the patient's blood for T-cell collection.Bridging therapy: Certain patients receive chemotherapy while waiting for CAR T cells to be produced.Lymphodepleting chemotherapy is administered before the injection to make room for CAR T cells. The patients should plan for potential hospitalisation, designate caretakers, and discuss long-term follow-up and expected adverse effects with the medical team.

  • T-cell harvesting: T cells are removed from the patient's blood by processing.
  • Genetic alteration: T cells are designed in the laboratory to express CAR proteins targeting cancer cells.
  • Expansion: Modified T cells are expanded to therapeutic levels.
  • Infusion: Patient receives an intravenous infusion of CAR T cells.
  • Monitoring: Intensive monitoring, often in the hospital, for side effects and reactions.

The whole process, from cell harvesting to infusion, can take three to six weeks. The infusion itself takes a few hours to a few minutes, but for at least one week following the infusion, close monitoring is required, and there will be frequent follow-ups for several months.

  • Cytokine Release Syndrome (CRS)
  • Neurotoxicity
  • Infections
  • Low blood counts
  • Relapse or non-response

One of the newer treatment options for some blood cancers is CAR T-cell therapy. It is utilised when other treatments are not working or the cancer recurs. CAR T-cell therapy has the potential to cure many blood cancers and extend life in most cases.

Recovery involves managing side effects like CRS and neurotoxicity, monitoring blood levels, and avoiding infections. Laboratory testing, imaging, and monitoring for late issues like hypogammaglobulinemia or relapse are all included in long-term follow-up.

The nature of the cancer, the burden of the disease, and an individual's response all impact success. For example, in pediatric acute lymphoblastic leukaemia, complete remission rates are more than 80%. However, relapse is always a risk, and long-term success is variable.

Would you like some help? We are available.

Get Help
Explore Hospitals ( 1 )
CAR-T in The London Clinic: Costs, Top Doctors, and Reviews

London, United Kingdom

  • Joint Commission International, or JCI

We, The London Clinic family, take pride in our reputation as a multi-disciplined healthcare facility. With skilled nurses and expert consultants, our medical teams are always focused to deliver the best individualized medical care. More than 1,000 nursing, clinical, and support staff are currently working with us to give our patients an extensive range of treatments. We use cutting-edge technologies to ensure a comprehensive range of healthcare services. Not only that, in order to make your stay with us comfortable enough, we equip our patient bedrooms with:

  • Electronic patient-controlled bed
  • En-suite bathroom
  • Air conditioning system
  • Remote-controlled television and radio
  • Telephone with direct dial facility
  • Nurse call system
  • Personal safe
  • Wi-fi

Patients from all over the world fly to us to get their procedures done by our specialist doctors, which is why we also provide our patient's concierge services. Our concierge services include:

  • Booking travel and hotel accommodation
  • Arranging London tour
  • Making theatre and restaurant reservation

The London Clinic has a zero-tolerance policy when it comes to hygiene and cleanliness. Our dedicated housekeeping team cleans every room every day between 8.00 am and 5.00 pm. They are also entitled to supply fresh towels every day and clean the rooms properly between patients.

We also have a day surgery unit based on the third floor at 20 Devonshire Place to make sure a hassle-free surgery as well as post-surgery care for our patients. Our cancer care unit at 22 Devonshire Place is also among our key services.

Need Some Advice From Our Experts?

Request a Call Back Now!

Our team of healthcare experts would be happy to assist you

trusted Patientstrusted Patients+99
Trusted by 50000+ Patients
Required | alphabets and spaces
Required | A valid, working email address
Required | A valid contact

Process Involved for CAR-T in United Kingdom

  • Preoperative Stage: An assessment of the patient's medical history, including testing to determine eligibility for CAR-T therapy and identify the target antigen on cancer cells.
  • Treatment Plan Discussion: An oncologist discusses the procedure of CAR-T therapy, including potential dangers, advantages, and side effects.
  • Therapeutic Stage: T-cells are extracted from the patient, modified in the lab to express a chimeric antigen receptor (CAR), and reintroduced into the patient to target and destroy cancer cells.
  • Postoperative Phase: Closely monitor for side effects. Follow-ups are scheduled regularly to check the response and treat any complications.
  • Cancer patients, especially those suffering from blood cancers like leukemia, lymphoma, and multiple myeloma.
  • Patients who have not responded to previous therapies, such as chemotherapy or radiation.
  • Patients in good overall health with a functioning immune system.
  • Individuals who have specific genetic markers that qualify them for CAR-T treatment.
  • Targeted Action: CAR-T treatment specifically targets cancer cells, increasing efficacy while minimising damage to healthy cells.
  • Potential for Remission: Can result in long-term remission, even in people with difficult-to-treat cancer.
  • Minimally Invasive: The treatment consists mainly of an outpatient procedure for T-cell collection, with the therapy provided via infusion.
  • Medical Oncologist
  • Fill out the inquiry form: Fill out the form to provide us with the relevant information about your condition.
  • Consult with Our Healthcare Expert: One of our qualified specialists will contact you for a consultation.
  • Receive a Detailed Treatment Plan: After examining your situation, we will provide you with a detailed treatment plan that includes expert views and cost breakdowns for various choices.
  • Choose your preferred option: Choose the treatment option that suits you the best.

Instantly Connect with our CAR-T Specialists

Doctor 1
Doctor 2
Doctor 3
Doctor 4
Doctor 5
Doctor 6
Doctor 7
Doctor 8
Our Services to Better your Experience

Opinion & Option

We submit the most accurate opinion and options from one or more countries for your review

Consult Privately

Consult with a certified specialist privately on our telemedicine platform even before you decide to travel

Logistics

We handle flights, visas, transfers, and accommodation—so you can focus on your health.

Recovery

Our In-house rehabilitation service packages to better your recovery and treatment outcome

Other Popular Countries for CAR-T

Our network connects you with the leading medical tourism destinations globally, offering a wide range of cities, top doctors, and flexible pricing options.

Turkey
Singapore
Malaysia
United Arab Emirates

Frequently Asked Questions

CAR-T cost in the United Kingdom varies from one hospital to the other. The top hospitals for CAR-T in the United Kingdom covers all the expenses related to the pre-surgery investigations of the candidate. The CAR-T package in the United Kingdom includes the fees of the surgeon, hospitalization and anesthesia as well. Post-surgical complications, new findings and delayed recovery may have an impact on the total CAR-T cost in the United Kingdom.

There are many hospitals that perform CAR-T in the United Kingdom. Some of the best hospitals for CAR-T in the United Kingdom include the following:

  1. The London Clinic

The recovery of the patient many vary, depending on several factors. However, on an average, patient is supposed to stay for about 30 days in the country after discharge. This is important to ensure that the surgery was successful. During this time, control and follow-up tests take place to check for medical fitness.

While the United Kingdom is considered to be one of the best destinations for CAR-T owing to the standard of Hospitals, and expertise of doctors; there are a select few destinations which provide comparable quality of healthcare for this procedure. Some of such countries are:

  1. Thailand
  2. Greece
  3. Czechia
  4. Spain
  5. India
  6. Lithuania
  7. Saudi Arabia
  8. the United Arab Emirates
  9. Malaysia
  10. Singapore

There are certain additional cost that the patient has to pay apart from the CAR-T cost. These include the cost of accommodation and meals outside hospital. The per day cost in this case may range around USD$ 55.

Some of the best cities in the United Kingdom which offer CAR-T are:

  • London

After CAR-T, the patient is supposed to stay for about 2 days in the hospital for recovery and monitoring. This time frame is important for the patient to recover properly and feel comfotable after the surgery. With the help of several tests, it is determined that the patient is doing fine after the surgery and is okay to be discharged.

Out of all the hospitals in the United Kingdom, there are about 1 best hospitals for CAR-T. These hospitals have the required expertise as well as infrastructure available to handly patients who need CAR-T

Author

Dr. Vishwas Kaushik

MBBS, MD

5 Years of Experience

Dr. Vishwas Kaushik is a qualified medical professional holding an MBBS from the prestigious Belgorod State University, Russia, with a strong foundation in clinical medicine and healthcare practice. His comprehensive medical training has equipped him with a profound understanding of evidence-based clinical practices, patient-centered care, and the evolving landscape of modern medicine. With a keen interest in medical research and scientific communication, he consistently translates complex clinical concepts into clear, accurate, and accessible content for diverse audiences. His work reflects a deep commitment to advancing medical knowledge, delivering impactful healthcare insights, and bridging the gap between clinical expertise and accessible medical communication.. View More

Reviewer

Dr Prateek Varshney

Surgical Oncologist

15 Years of Experience

Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practicing as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute. View More